Colgate Palmolive: 2Q 2026 Earnings Presentation (50bca6)
Colgate-Palmolive released its Q2 2026 earnings presentation (July 31, 2026). The company reported net sales up 4.9% and organic sales up 2.4% (non-GAAP), with base business EPS up 8% and free cash flow up 18% year to date. It raised 2026 guidance, projecting GAAP EPS up double digits and non-GAAP organic sales growth of 1% to 4%.
How this was made
The 30-second read
Why it matters
The presentation highlights stronger-than-expected operating metrics (sales, base business EPS, operating profit, and free cash flow) and provides updated 2026 guidance for net sales growth, gross margin (roughly flat), advertising intensity, and GAAP and non-GAAP EPS direction. It also discloses the expected cost and savings profile of a three-year productivity program, which can affect investor views on margin durability and cash conversion.
Market read
Traders can use the quantified 2Q performance and explicit 2026 guidance ranges to update expectations for EPS, margins, and free cash flow, while monitoring execution risk around the productivity program charges.
What to watch
Organic growth is modest (+2.4%) and includes a negative private-label pet food impact from an exited business; investors may focus on whether toothpaste share gains translate into sustained pricing and margin.
Background
This is Colgate Palmolive’s 2Q 2026 earnings presentation, emphasizing non-GAAP base business metrics, organic sales, and a 2030 strategy with a multi-year strategic growth and productivity program.
Ticker impact
Colgate Palmolive reports 2Q 2026 net sales +4.9% and raises/updates 2026 guidance, including GAAP EPS up double digits and base-business EPS up mid-single digits.
Moderately positive bias for near-term trading as investors reprice 2026 EPS and free-cash-flow durability, offset by execution risk from the productivity charges.
The article provides multiple quantified 2Q results (sales, base business EPS, free cash flow) plus explicit 2026 GAAP and non-GAAP guidance ranges and a defined multi-year productivity program with charge/savings expectations.
Market effects
Signals resilience in consumer staples oral/personal/home categories despite a “very challenging operating environment,” potentially supporting sentiment for branded consumer health names.
Global portfolio framing and FX-adjusted guidance may influence how traders model developed vs emerging demand sensitivity.
Advertising spend increase and omni-channel demand generation emphasis can affect broader CPG marketing spend expectations.
Counterpoint
The guidance still depends on volatile conditions and includes sizable pre-tax charges ($350 to $550 million) through 2028, so near-term EPS confidence may be overstated if execution slips.
Key entities
- companyColgate-Palmolive
Reports 2Q 2026 results and updates 2026 guidance, including GAAP EPS up double digits and base business EPS up mid-single digits.
- executiveNoel Wallace
Chairman, President and CEO, quoted on investment levels and confidence in compounded EPS growth through 2030 strategy.
